Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
A complement-dependent balance between hepatic ischemia/reperfusion injury and liver regeneration in mice
Songqing He, Carl Atkinson, Fei Qiao, Katherine Cianflone, Xiaoping Chen, Stephen Tomlinson
Songqing He, Carl Atkinson, Fei Qiao, Katherine Cianflone, Xiaoping Chen, Stephen Tomlinson
View: Text | PDF
Research Article Hepatology

A complement-dependent balance between hepatic ischemia/reperfusion injury and liver regeneration in mice

  • Text
  • PDF
Abstract

Massive liver resection and small-for-size liver transplantation pose a therapeutic challenge, due to increased susceptibility of the remnant/graft to ischemia reperfusion injury (IRI) and impaired regeneration. We investigated the dual role of complement in IRI versus regeneration in mice. Complement component 3 (C3) deficiency and complement inhibition with complement receptor 2–complement receptor 1–related protein y (CR2-Crry, an inhibitor of C3 activation) provided protection from hepatic IRI, and while C3 deficiency also impaired liver regeneration following partial hepatectomy (PHx), the effect of CR2-Crry in this context was dose dependent. In a combined model of IRI and PHx, either C3 deficiency or high-dose CR2-Crry resulted in steatosis, severe hepatic injury, and high mortality, whereas low-dose CR2-Crry was protective and actually increased hepatic proliferative responses relative to control mice. Reconstitution experiments revealed an important role for the C3a degradation product acylation-stimulating protein (ASP) in the balance between inflammation/injury versus regeneration. Furthermore, liver regeneration was dependent on the putative ASP receptor, C5L2. Several potential mechanisms of hepatoprotection and recovery were identified in mice treated with low-dose CR2-Crry, including enhanced IL-6 expression and STAT3 activation, reduced hepatic ATP depletion, and attenuated oxidative stress. These data indicate that a threshold of complement activation, involving ASP and C5L2, promotes liver regeneration and suggest a balance between complement-dependent injury and regeneration.

Authors

Songqing He, Carl Atkinson, Fei Qiao, Katherine Cianflone, Xiaoping Chen, Stephen Tomlinson

×

Figure 8

Effect of C3 deficiency and complement inhibition on hepatic and serum levels of TNF-α and IL-6 following IRI and PHx.

Options: View larger image (or click on image) Download as PowerPoint
Effect of C3 deficiency and complement inhibition on hepatic and serum l...
Mice were treated with normal saline or CR2-Crry at a dose of either 0.25 mg or 0.08 mg immediately after surgery. C3–/– mice received no treatment. (A) Serum TNF-α levels 6 hours after PHx. (B) Serum IL-6 levels 6 hours after PHx. (C) Serum TNF-α levels 48 hours after PHx. (D) Serum IL-6 levels 48 hours after PHx. (E) Hepatic TNF-α levels 3 hours after PHx. (F) Hepatic IL-6 levels 3 hours after PHx. Low-dose CR2-Crry treatment was associated with high hepatic levels of IL-6 and TNF-α early after PHx relative to other groups and lower relative serum cytokine levels by 48 hours after PHx. #P < 0.05, ##P < 0.01 versus WT group; *P < 0.05, **P < 0.01 versus WT group (similar to WT normal saline group); ††P < 0.01 versus CR2-Crry 0.25 mg and C3–/– groups. Results are expressed as mean ± SD; n = 6 for all groups.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts